Do analysts recommend PRQR or BKHA?

ProQR Therapeutics presently has a consensus price target of $7.50, suggesting a potential upside of 338.60%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Black Hawk Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, PRQR or BKHA?

Black Hawk Acquisition has lower revenue, but higher earnings than ProQR Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProQR Therapeutics $17.99M 10.01 -$47.73M -$0.46 N/A Black Hawk Acquisition N/A N/A N/A N/A N/A

Does the media prefer PRQR or BKHA?

In the previous week, ProQR Therapeutics had 1 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 4 mentions for ProQR Therapeutics and 3 mentions for Black Hawk Acquisition. ProQR Therapeutics' average media sentiment score of 0.45 beat Black Hawk Acquisition's score of 0.35 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Black Hawk Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SRZN or BKHA?

Surrozen presently has a consensus target price of $45.00, indicating a potential upside of 33.61%. Given Surrozen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Surrozen is more favorable than Black Hawk Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surrozen 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, SRZN or BKHA?

Black Hawk Acquisition has lower revenue, but higher earnings than Surrozen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Surrozen $3.48M 112.36 -$242.03M -$40.55 N/A Black Hawk Acquisition N/A N/A N/A N/A N/A

Is SRZN or BKHA more profitable?

Black Hawk Acquisition has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Company Net Margins Return on Equity Return on Assets Surrozen -2,885.33% N/A -93.62% Black Hawk Acquisition N/A N/A N/A

Does the media prefer SRZN or BKHA?

In the previous week, Surrozen had 1 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 4 mentions for Surrozen and 3 mentions for Black Hawk Acquisition. Surrozen's average media sentiment score of 0.67 beat Black Hawk Acquisition's score of 0.35 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Hawk Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BKHA or TNXP?

Tonix Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 152.58%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Black Hawk Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tonix Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has preferable earnings and valuation, BKHA or TNXP?

Black Hawk Acquisition has higher earnings, but lower revenue than Tonix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Hawk Acquisition N/A N/A N/A N/A N/A Tonix Pharmaceuticals $29.10M 5.72 -$124.02M -$12.94 N/A

Does the media favor BKHA or TNXP?

In the previous week, Tonix Pharmaceuticals had 2 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 5 mentions for Tonix Pharmaceuticals and 3 mentions for Black Hawk Acquisition. Black Hawk Acquisition's average media sentiment score of 0.35 beat Tonix Pharmaceuticals' score of 0.32 indicating that Black Hawk Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Hawk Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tonix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ORMP or BKHA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ORMP or BKHA?

Oramed Pharmaceuticals has higher revenue and earnings than Black Hawk Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oramed Pharmaceuticals $2M 99.63 $64.05M $4.12 1.16 Black Hawk Acquisition N/A N/A N/A N/A N/A

Is ORMP or BKHA more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.17% -4.54% Black Hawk Acquisition N/A N/A N/A

Do analysts prefer BKHA or CHRS?

Coherus Oncology has a consensus target price of $11.00, suggesting a potential upside of 840.17%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than Black Hawk Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Coherus Oncology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger earnings & valuation, BKHA or CHRS?

Coherus Oncology has higher revenue and earnings than Black Hawk Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Hawk Acquisition N/A N/A N/A N/A N/A Coherus Oncology $42.17M 4.29 $168.02M -$1.03 N/A

Does the media favor BKHA or CHRS?

In the previous week, Coherus Oncology had 1 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 4 mentions for Coherus Oncology and 3 mentions for Black Hawk Acquisition. Coherus Oncology's average media sentiment score of 0.67 beat Black Hawk Acquisition's score of 0.35 indicating that Coherus Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Hawk Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coherus Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Black Hawk Acquisition (BKHA) Competitors

$12.47 +0.37 (+3.07%)

As of 03:50 PM Eastern

Compare

BKHA vs. PRQR, SRZN, TNXP, ORMP, and CHRS

Should you buy Black Hawk Acquisition stock or one of its competitors? Black Hawk Acquisition's main competitors and comparable companies include ProQR Therapeutics (PRQR), Surrozen (SRZN), Tonix Pharmaceuticals (TNXP), Oramed Pharmaceuticals (ORMP), and Coherus Oncology (CHRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Black Hawk Acquisition compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Black Hawk Acquisition (NASDAQ:BKHA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Black Hawk Acquisition has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -223.51%. Black Hawk Acquisition's return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
Black Hawk Acquisition	N/A	N/A	N/A

ProQR Therapeutics has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market. Comparatively, Black Hawk Acquisition has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

32.7% of ProQR Therapeutics shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, ProQR Therapeutics had 1 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 4 mentions for ProQR Therapeutics and 3 mentions for Black Hawk Acquisition. ProQR Therapeutics' average media sentiment score of 0.45 beat Black Hawk Acquisition's score of 0.35 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Black Hawk Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ProQR Therapeutics presently has a consensus price target of $7.50, suggesting a potential upside of 338.60%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Black Hawk Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Black Hawk Acquisition has lower revenue, but higher earnings than ProQR Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.01	-$47.73M	-$0.46	N/A
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

ProQR Therapeutics beats Black Hawk Acquisition on 9 of the 12 factors compared between the two stocks.

How does Black Hawk Acquisition compare to Surrozen?

Surrozen (NASDAQ:SRZN) and Black Hawk Acquisition (NASDAQ:BKHA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Black Hawk Acquisition has lower revenue, but higher earnings than Surrozen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	112.36	-$242.03M	-$40.55	N/A
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Surrozen had 1 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 4 mentions for Surrozen and 3 mentions for Black Hawk Acquisition. Surrozen's average media sentiment score of 0.67 beat Black Hawk Acquisition's score of 0.35 indicating that Surrozen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Hawk Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

66.6% of Surrozen shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Black Hawk Acquisition has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
Black Hawk Acquisition	N/A	N/A	N/A

Surrozen presently has a consensus target price of $45.00, indicating a potential upside of 33.61%. Given Surrozen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Surrozen is more favorable than Black Hawk Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Surrozen has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Black Hawk Acquisition has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market.

Summary

Surrozen beats Black Hawk Acquisition on 10 of the 12 factors compared between the two stocks.

How does Black Hawk Acquisition compare to Tonix Pharmaceuticals?

Black Hawk Acquisition (NASDAQ:BKHA) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

In the previous week, Tonix Pharmaceuticals had 2 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 5 mentions for Tonix Pharmaceuticals and 3 mentions for Black Hawk Acquisition. Black Hawk Acquisition's average media sentiment score of 0.35 beat Tonix Pharmaceuticals' score of 0.32 indicating that Black Hawk Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Hawk Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tonix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tonix Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 152.58%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Black Hawk Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Black Hawk Acquisition has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market.

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Black Hawk Acquisition has higher earnings, but lower revenue than Tonix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
Tonix Pharmaceuticals	$29.10M	5.72	-$124.02M	-$12.94	N/A

Black Hawk Acquisition has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Black Hawk Acquisition's return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Hawk Acquisition	N/A	N/A	N/A
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

Summary

Tonix Pharmaceuticals beats Black Hawk Acquisition on 8 of the 12 factors compared between the two stocks.

How does Black Hawk Acquisition compare to Oramed Pharmaceuticals?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Black Hawk Acquisition (NASDAQ:BKHA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Black Hawk Acquisition's return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%
Black Hawk Acquisition	N/A	N/A	N/A

Oramed Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Black Hawk Acquisition has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Black Hawk Acquisition had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 3 mentions for Black Hawk Acquisition and 1 mentions for Oramed Pharmaceuticals. Black Hawk Acquisition's average media sentiment score of 0.35 beat Oramed Pharmaceuticals' score of 0.00 indicating that Black Hawk Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Oramed Pharmaceuticals	Neutral
Black Hawk Acquisition	Neutral

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Oramed Pharmaceuticals has higher revenue and earnings than Black Hawk Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	99.63	$64.05M	$4.12	1.16
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Oramed Pharmaceuticals beats Black Hawk Acquisition on 5 of the 9 factors compared between the two stocks.

How does Black Hawk Acquisition compare to Coherus Oncology?

Black Hawk Acquisition (NASDAQ:BKHA) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

72.8% of Coherus Oncology shares are held by institutional investors. 7.2% of Coherus Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Coherus Oncology has a consensus target price of $11.00, suggesting a potential upside of 840.17%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than Black Hawk Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Coherus Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Coherus Oncology has higher revenue and earnings than Black Hawk Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
Coherus Oncology	$42.17M	4.29	$168.02M	-$1.03	N/A

Black Hawk Acquisition has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Black Hawk Acquisition has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Black Hawk Acquisition's return on equity of 0.00% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Hawk Acquisition	N/A	N/A	N/A
Coherus Oncology	-259.41%	-222.75%	-52.11%

In the previous week, Coherus Oncology had 1 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 4 mentions for Coherus Oncology and 3 mentions for Black Hawk Acquisition. Coherus Oncology's average media sentiment score of 0.67 beat Black Hawk Acquisition's score of 0.35 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Hawk Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coherus Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Coherus Oncology beats Black Hawk Acquisition on 9 of the 12 factors compared between the two stocks.

Get Black Hawk Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BKHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BKHA vs. The Competition

Export

Metric	Black Hawk Acquisition	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$50.26M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	N/A	14.00	274.40	25.76
Price / Sales	N/A	1,346.15	639.79	86.88
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	N/A	15.46	10.52	6.34
Net Income	N/A	-$22.82M	$3.49B	$360.00M
7 Day Performance	4.06%	-2.21%	-1.08%	-0.11%
1 Month Performance	5.29%	-6.66%	-3.39%	-3.42%
1 Year Performance	12.06%	30.99%	15.08%	5.46%

Black Hawk Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BKHA Black Hawk Acquisition	N/A	$12.47 +3.1%	N/A	+9.0%	$50.26M	N/A	N/A	N/A	News Coverage Short Interest Decrease
PRQR ProQR Therapeutics	4.0089 of 5 stars	$1.83 -3.2%	$7.50 +309.8%	-21.3%	$199.13M	$17.99M	N/A	166	News Coverage
SRZN Surrozen	2.9029 of 5 stars	$16.55 -2.3%	$45.00 +171.9%	+33.8%	$196.68M	$3.48M	N/A	44	Short Interest Increase Gap Up
TNXP Tonix Pharmaceuticals	4.1436 of 5 stars	$10.87 -4.8%	$24.50 +125.4%	-59.5%	$195.86M	$29.10M	N/A	142	High Trading Volume
ORMP Oramed Pharmaceuticals	1.6208 of 5 stars	$4.74 +1.5%	N/A	+89.6%	$194.26M	$2M	1.15	13	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BKHA) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Black Hawk Acquisition (BKHA) Competitors

BKHA vs. PRQR, SRZN, TNXP, ORMP, and CHRS

How does Black Hawk Acquisition compare to ProQR Therapeutics?

Summary

How does Black Hawk Acquisition compare to Surrozen?

Summary

How does Black Hawk Acquisition compare to Tonix Pharmaceuticals?

Summary

How does Black Hawk Acquisition compare to Oramed Pharmaceuticals?

Summary

How does Black Hawk Acquisition compare to Coherus Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BKHA vs. The Competition

Black Hawk Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Black Hawk Acquisition (BKHA) Competitors

BKHA vs. PRQR, SRZN, TNXP, ORMP, and CHRS

How does Black Hawk Acquisition compare to ProQR Therapeutics?

Is PRQR or BKHA more profitable?

Which has more risk and volatility, PRQR or BKHA?

Do insiders and institutionals have more ownership in PRQR or BKHA?

Does the media prefer PRQR or BKHA?

Do analysts recommend PRQR or BKHA?

Which has better earnings and valuation, PRQR or BKHA?

Summary

How does Black Hawk Acquisition compare to Surrozen?

Which has stronger valuation & earnings, SRZN or BKHA?

Does the media prefer SRZN or BKHA?

Do institutionals & insiders believe in SRZN or BKHA?

Is SRZN or BKHA more profitable?

Do analysts rate SRZN or BKHA?

Which has more volatility & risk, SRZN or BKHA?

Summary

How does Black Hawk Acquisition compare to Tonix Pharmaceuticals?

Does the media favor BKHA or TNXP?

Do analysts recommend BKHA or TNXP?

Which has more risk & volatility, BKHA or TNXP?

Do institutionals & insiders have more ownership in BKHA or TNXP?

Which has preferable earnings and valuation, BKHA or TNXP?

Is BKHA or TNXP more profitable?

Summary

How does Black Hawk Acquisition compare to Oramed Pharmaceuticals?

Is ORMP or BKHA more profitable?

Which has more risk and volatility, ORMP or BKHA?

Do analysts recommend ORMP or BKHA?

Does the media refer more to ORMP or BKHA?

Do institutionals and insiders have more ownership in ORMP or BKHA?

Which has stronger valuation and earnings, ORMP or BKHA?

Summary

How does Black Hawk Acquisition compare to Coherus Oncology?

Do institutionals and insiders have more ownership in BKHA or CHRS?

Do analysts prefer BKHA or CHRS?

Which has stronger earnings & valuation, BKHA or CHRS?

Which has more volatility & risk, BKHA or CHRS?

Is BKHA or CHRS more profitable?

Does the media favor BKHA or CHRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BKHA vs. The Competition

Black Hawk Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools